About the Company
Axovant Gene Therapies Ltd. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focus on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis such as Tay-Sachs disease and Sandhoff disease. Axovant operates through seven wholly owned subsidiaries and also has business operations in Basel, Switzerland and New York, NY. The company was founded on October 31, 2014 and is headquartered in London, United Kingdom.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AXGT News
Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 Gangliosidosis
Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it has received Rare Pediatric Disease ...
Buzz for gene therapies is loud, but drugmakers struggle to get treatments off the ground
Made by BioMarin Pharmaceutical, the therapy marked the company's first moves into gene therapies that seek to correct genetic conditions and treat inherited disorders. But, Roctavian so far hasn ...
Evaluating Transformative Gene Therapies
Ryan Haumschild, PharmD, MS, MBA, and Mary Pak, MD, FACP, consider FDA-approved gene therapies for hemophilia, spinal muscular atrophy, and Duchenne muscular dystrophy, exploring their genetic ...
Hemophilia gene therapies arrived after 40 years of struggle. Where are the patients?
His doctor walked through various experimental approaches for the bleeding disorder and, invariably, gene therapy. It was coming, he always said, in your lifetime. Last year, it finally arrived.
First gene therapy tests in whole human liver
Gene therapy is a revolutionary approach to treating serious genetic diseases that most commonly involves replacing or repairing a faulty gene. The most efficient delivery systems today are those ...
Gene Therapy News
6, 2024 — A specific gene may play a key role in new treatments that prevent muscle in the body from breaking down in serious muscle diseases, muscular ... A Better Way to Deliver Fetal Therapy ...
Taysha Gene Therapies (NASDAQ: TSHA)
Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies ...
The Fight to Pay for Gene Therapy
Conner Hess and his family at Boston Children’s Hospital, which administered a new gene therapy for adrenoleukodystrophy. Photo-Illustration: Courtesy of Richelle Brooks “I was a really ...
Gene therapy articles from across Nature Portfolio
Gene therapy involves the introduction of new genes into cells, to restore or add gene expression, for the purpose of treating disease. Most commonly a mutated gene is replaced with DNA encoding a ...
Market and Reimbursement Outlook for Cell and Gene Therapies
Cell and gene therapies are a scientific advancement that can treat previously uncurable diseases. Yet absent a national coverage and payment framework, they will remain out of reach for patients ...
Loading the latest forecasts...